<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049707</url>
  </required_header>
  <id_info>
    <org_study_id>#21D.124</org_study_id>
    <nct_id>NCT05049707</nct_id>
  </id_info>
  <brief_title>Does Perioperative Intravenous Magnesium Affect Postoperative Quality of Recovery in Craniotomy Surgery Patients?</brief_title>
  <official_title>Does Perioperative Intravenous Magnesium Affect Postoperative Quality of Recovery in Elective Craniotomy Surgery Patients?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perioperative pain management for craniotomy patients may be challenging because the commonly&#xD;
      used agents such as opioids, gabapentin, and dexmedetomidine also cause sedation, which can&#xD;
      confound the neurological exam and can lead to respiratory depression and increased&#xD;
      intracranial pressure. Preoperative intravenous magnesium boluses and infusions have&#xD;
      previously been established as an effective, nonsedating analgesic that can reduce opioid&#xD;
      consumption 25-30% up to 48 hours postoperatively.&#xD;
&#xD;
      However, intravenous magnesium has not seen widespread use in craniotomy patients due to&#xD;
      concerns for interference with the neurological monitoring that commonly occurs in these&#xD;
      cases. Intravenous magnesium given as a bolus preoperatively or as a constant infusion may&#xD;
      avoid these problems and has never been investigated.&#xD;
&#xD;
      The goal of this study is to compare intravenous magnesium given preoperatively and&#xD;
      intraoperatively to placebo in adult elective craniotomy patients to improve quality of&#xD;
      recovery postoperatively, and evaluate safety and tolerability. Secondary endpoints will&#xD;
      include evaluating for pain, sedation, agitation, blood pressure, and opioid consumption&#xD;
      postoperatively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, randomized, controlled, and double-blinded clinical trial&#xD;
      comparing clinical outcomes of craniotomy patients who receive a 50mg/kg bolus of intravenous&#xD;
      magnesium followed by a magnesium infusion of 15mg/kg/hr to a placebo group of patients who&#xD;
      will receive a saline bolus and infusion of equivalent volume. The sample size calculations&#xD;
      are based on an effect size 24 point increase in Quality of Recovery-40 Questionnaire scores&#xD;
      from a previous randomized control trial featuring the same bolus and infusion regimen as&#xD;
      this trial. Investigators, patients, and providers will be blinded. Patients over the age of&#xD;
      18 undergoing elective craniotomy surgery will be enrolled.&#xD;
&#xD;
      The study population will consist of patients undergoing elective craniotomy surgery. The&#xD;
      inclusion criteria consists of patient age 18-85, ASA (American Society of Anesthesiologists)&#xD;
      Physical Status Classification 1-3, with Glasgow Coma Scale (GCS) of 15 with adequate english&#xD;
      comprehension. Exclusion criteria includes pregnant or nursing patients, patients with known&#xD;
      allergies to any of the study drugs, patient's refusal, patients with a history of cirrhosis,&#xD;
      chronic kidney disease stage 3 or higher, known history of substance abuse, neuromuscular&#xD;
      disease or heart block.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Recovery Questionnaire 40</measure>
    <time_frame>Postoperative days 0-2</time_frame>
    <description>Validated measure of postoperative quality of recovery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypertension Postoperative</measure>
    <time_frame>postoperative days 0-2</time_frame>
    <description>systolic blood pressure &gt; 160</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Hyperglycemia</measure>
    <time_frame>Postoperative days 0-2</time_frame>
    <description>glucose &gt; 180</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications Possibly Related to Intraoperative Neuromonitoring</measure>
    <time_frame>postoperative days 0-2</time_frame>
    <description>We will monitor for rates of complications postoperatively, noting whether or not they could have been detected by intraoperative neuromonitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shivering</measure>
    <time_frame>First 2 hours in the postoperative care unit or intensive care unit</time_frame>
    <description>Bedside Shivering Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Brain Tumor</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control arm will receive an equivalent volume of normal saline as the treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV magnesium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We will randomize patients in the treatment group to receive either a 50 mg/kg bolus of intravenous magnesium preoperatively followed by a magnesium infusion of 15mg/kg/hr, to be given after intraoperative neuromonitoring staff have been able to record baseline neurological data.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV magnesium sulfate</intervention_name>
    <description>10 grams magnesium in 250 cc normal saline</description>
    <arm_group_label>IV magnesium</arm_group_label>
    <other_name>Magnesium Sulfate IV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>250 cc normal saline delivered in equivalent rates as the treatment group</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient age 18-85&#xD;
&#xD;
          -  ASA (American Society of Anesthesiologists) Physical Status Classification 1-3&#xD;
&#xD;
          -  Glasgow Coma Scale (GCS) of 15&#xD;
&#xD;
          -  Adequate english comprehension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or nursing patients&#xD;
&#xD;
          -  patients with known allergies to any of the study drugs&#xD;
&#xD;
          -  patient's refusal&#xD;
&#xD;
          -  patients with a history of cirrhosis&#xD;
&#xD;
          -  chronic kidney disease stage 3 or higher&#xD;
&#xD;
          -  known history of substance abuse&#xD;
&#xD;
          -  history of neuromuscular disease&#xD;
&#xD;
          -  history of heart block&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Min, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin J Min, MD</last_name>
    <phone>631-485-2542</phone>
    <email>kevin.min@jefferson.edu</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thomas Jefferson University</investigator_affiliation>
    <investigator_full_name>Kevin Min</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

